Epidemiological, Clinical and Laboratory Aspects of Infectious Processes Caused by Sars-Cov-2
Since December 2019, COVID-19 (coronavirus disease 2019) originating in Wuhan, China, caused by SARS-CoV-2, responsible for severe acute respiratory syndrome, has become a major global public health problem. The presentation of these diseases ranges from asymptomatic to severe cases, which may lead to death. Such differences in pictures are due to both clinical and epidemiological factors. This study aims to evaluate epidemiological, clinical and laboratory information from patients in the community with a positive result for the coronavirus obtained at a primary laboratory in Juiz de Fora/Minas Gerais. This research was based on the analysis of data from individuals of both sexes, over 18 years old, exclusively outpatients, with a positive result for COVID-19. This study showed a predominance of male individuals as carriers of SARS-CoV-2 (65%, n=13) and a mean age of 41.9 years, ranging from 28 to 64 years. According to the medical records, all evaluated patients had some symptoms for COVID-19, the most frequent being myalgia (50%, n=10), fever and cough (45%, n=9, both). Regarding comorbidities, the most prevalent were alcoholism (25%, n=5) and systemic arterial hypertension (25%, n=5), with a portion also presenting upper respiratory tract disease 10%, n=2). The biomarkers (red cells, hemoglobin, hematocrit, white blood cells, eosinophils, rods neutrophils, segmented neutrophils,
lymphocytes, platelets, fibrinogen, partial thromboplastin time, prothrombin time, lactate dehydrogenase, ferritin, D-dimer and C-reactive protein) determined 14 days after diagnosis of COVID-19 were mostly within the reference or negative values. From this research, it was concluded that the clinical, epidemiological and laboratory data are compatible with clinical findings in the literature on mild cases of COVID-19.
Keywords: COVID-19; SARS-CoV-2; Epidemiology; Laboratory Biomarkers.
*Não disponível em português.
Para acessar o artigo na integra, clique aqui!